Articles highlighting global pharmaceutical market issues.
- End of the Road for UK Price Regulation Scheme?
Cambridge Pharma considers the outlook for the UK Pharmaceutical Price Regulation Scheme, designed to keep drugs affordable for the state-run health service.
Apr 29, 2007
- IMS Retail Drug Monitor - February 2007
The February edition of IMS Retail Drug Monitor shows a 5% growth in drug sales through retail pharmacies in 13 key markets in the 12-month period from March 2006 through to February 2007, closing at US$ 392 billion.
Apr 23, 2007
- IMS Retail Drug Monitor - January 2007
The January edition of IMS Retail Drug Monitor shows a 5% growth in drug sales through retail pharmacies in 13 key markets in the 12-month period from February 2006 through to January 2007, closing at US$ 390.2 billion.
Apr 10, 2007
- IMS Retail Drug Monitor May 2007
The May edition of IMS Retail Drug Monitor shows a 5% growth in drug sales through retail pharmacies in 13 key markets in the 12-month period from June 2006 through to May 2007, closing at US$ 399.5 billion.
Apr 8, 2007
- IMS Retail Drug Monitor April 2007
The April edition of IMS Retail Drug Monitor shows a 5% growth in drug sales through retail pharmacies in 13 key markets in the 12-month period from May 2006 through to April 2007, closing at US$ 398.01 billion.
Apr 5, 2007
- Changing market dynamics in 2007
Emerging markets, biotechs, generics and specialty-initiated products are all expected to see robust growth over 2007.
Dec 5, 2006
- New products and markets fuel growth in 2005
IMS’ annual sales review reveals moderated growth overall in 2005, but increasing impetus from developing markets and new products.
May 8, 2006
- The five components of launch success
Planning ahead is key to ensuring the successful launch of a new pharmaceutical product.
Dec 15, 2005
- Biotech in Canada - striving to reach potential
A look at the issues that arose from the domestic industry during the BioFinance 2005 meeting, held in Toronto, including access to finance, corporate governance, and the importation of drugs to the US.
Aug 2, 2005
- No more sleepless nights for Sepracor?
Sales of Lunesta, the first sleeping pill that can be taken long term, have got off to a flying start – but new competitors are nigh.
Jul 29, 2005
- New Active Substances Plateau in 2004
Just one more new drug was launched in 2004 over 2003, but there were signs of a growing contribution from new regions.
May 23, 2005
- Looking to China and Cancer As Cost Containment Slows Growth
In 2004, the global pharmaceutical market reached a record $550bn, but growth slowed to just 7%.
Apr 5, 2005
- Latin America: Overcoming Economic Challenges
IMS predicts solid growth for the major pharmaceutical markets in Latin America as local economies improve though cost-containment and healthcare reforms are among some of the major issues in the region.
Nov 26, 2004
- Could Indian Drugmakers TRIP on Patent Reform?
Prior to the introduction of product patents in India from January 2005 the first Exclusive Marketing Rights have been granted - IMS looks at why both multinationals and domestic manufacturers are dissatisfied.
Oct 27, 2004
- Australasia Braces for Patent Reform
According to the new IMS Market Prognosis Australasia report aggregate sales in the 12 markets covered will grow at a CAGR of 4.6% from 2003-2008 though there are wide disparities between individual markets.
May 17, 2004
- Lipitor Leads the Way in 2003
IMS' new World Review reveals that audited global pharma sales grew 9% to reach $466 billion in 2003 with cholesterol drugs led by Lipitor overtaking antiulcerants to become the top therapy class.
Mar 18, 2004
- Tough Love: German Healthcare Reform
IMS' Country Manager Germany Elisabeth Beck agrees that the local healthcare system was in need of reform but has Chancellor Schroeder's government got the balance right?
Feb 26, 2004
- US Market Share Continues to Expand
Despite cost-containment policies from US healthcare providers and payers IMS Market Prognosis International believes the world's largest single pharmaceutical market will continue to expand.
Jan 12, 2004
- Healthcare Reforms Precede EU Accession in Central and Eastern Europe
IMS Market Prognosis Central and Eastern Europe details the healthcare challenges facing a number of countries as they prepare to enter the European Union including cost-containment and reform.
Jan 6, 2004
- Is the Pharma Industry Weathering the 'Perfect Storm?'
The global pharmaceutical industry is facing an unprecedented set of challenges including poor R&D productivity and loss of exclusivity for blockbuster drugs - IMS reviews its R&D performance in 2002.
Mar 17, 2003
- 2002 World Pharma Sales Growth: Slower, But Still Healthy
Despite economic challenges in many leading markets and fewer new product launches audited global pharma sales grew 8% in 2002 to reach $400.6 billion according to the new IMS World Review.
Feb 28, 2003
- Shake-Up for US Antihistamine Market
Schering-Plough's blockbuster antihistamine Claritin went over-the-counter in the US in December 2002 shortly before its exclusivity expired... how will this impact the market?
Dec 18, 2002
- World Pharma Sales 2001: US Still Driving Growth
Based on the new IMS World Review, global audited pharma sales grew 12% in 2001 to reach $364.2 billion. North America was again the most dynamic region, with 17% growth to $181.8 billion - half of all global sales.
Apr 30, 2002
- Industry Experts Predict Imminent R&D Paradigm Shift
IMS Health data shows that despite the number of NASs reaching a 20-year low in 2001 biotechnology made up 30% and industry experts predict biotechs will make much bigger contribution future.
Apr 12, 2002
- Vigorous Growth Returns to Latin America
The Latin American pharmaceutical market experienced renewed growth in 2000 helped in no small measure by a strong dose of Viagra.
Mar 15, 2001
